KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells
Disease and Therapeutics · 2026
DOI: 10.1016/j.dist.2026.100025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease and Therapeutics, 2026. Verfasst von Nobuyuki Fujiwara und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fujiwara, N., Oya, R., Tsunedomi, R., Matsuda, A., Hayakawa, K., Kobayashi, K., & Ohama, T. (2026). KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. https://doi.org/10.1016/j.dist.2026.100025
Vancouver
Fujiwara N, Oya R, Tsunedomi R, Matsuda A, Hayakawa K, Kobayashi K, et al. KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells. Disease and Therapeutics. 2026. doi:10.1016/j.dist.2026.100025
BibTeX
@article{Fujiwara2026,
author = {Fujiwara, Nobuyuki and Oya, Ryo and Tsunedomi, Ryouichi and Matsuda, Akira and Hayakawa, Koji and Kobayashi, Kosuke and Ohama, Takashi},
title = {KRAS Q61H drives acquired resistance to toceranib through sustained RAS–MAPK signaling in canine mast cell tumor cells},
journal = {Disease and Therapeutics},
year = {2026},
doi = {10.1016/j.dist.2026.100025}
}
EUVIMED